AgomAb Therapeutics NV (AGMB) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), AgomAb Therapeutics NV had return on equity of -39.2% (down from -27.3%), debt-to-equity of 0.01 (up from 0.01), a current ratio of 6.52 (down from 19.05) and return on assets of -20.6% (down from -15.9%). A current ratio of 6.52 means current assets exceed current liabilities.

AgomAb Therapeutics NV Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Jan 2022	Dec 2019	Dec 2018
Valuation Ratios
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)	-39.22%	-27.25%	-10.46%	-	-	-90.33%	-1901.98%
Return on Assets (ROA)	-20.58%	-15.90%	-14.32%	-	-	-49.38%	-139.78%
Return on Capital Employed (ROCE)	-43.90%	-24.30%	-19.40%	-31.80%	-	-41.30%	-295.40%
Leverage & Solvency Ratios
Debt/Equity	0.01	0.01	0.01	0.00	-	-	1.50
Liquidity Ratios
Current Ratio	6.52	19.05	12.81	2.39	-	-	1.67
Quick Ratio	6.49	19.02	12.80	2.39	-	-	1.67
Efficiency Ratios
Yield & Distribution Ratios
Buyback Yield	-	-	0.00%	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AgomAb Therapeutics NV Financial Ratios

What is AgomAb Therapeutics NV's return on equity?

AgomAb Therapeutics NV's return on equity (ROE) was -39.2% for fiscal 2025 (period ended Dec 31, 2025). It was -27.3% a year earlier.

What is AgomAb Therapeutics NV's debt-to-equity ratio?

AgomAb Therapeutics NV's debt-to-equity ratio was 0.01 for fiscal 2025 (period ended Dec 31, 2025). It was 0.01 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition